Drug Profile
Ad26.ZIKV.001
Alternative Names: JNJ-66684657Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Janssen Vaccines and Prevention B.V
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Zika-virus-infection(In volunteers) in USA (IM, Injection)
- 23 Sep 2019 Janssen completes a phase I trial in Zika virus infection (In volunteers) in USA (IM) (NCT03356561)
- 26 Nov 2017 Phase-I clinical trials in Zika virus infection (In volunteers) in USA (IM) (NCT03356561)